Acquisition of cGMP-grade GS-441524 for the Treatment of COVID-19
Closed Solicitation Posted
- Solicitation number
- 75N95022Q00102
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
Notice details come from SAM.gov. Updated .
About this opportunity
This combined synopsis/solicitation from the National Institute on Drug Abuse, on behalf of the National Center for Advancing Translational Sciences, seeks to procure approximately 2-3 kilograms of cGMP-grade GS-441524 drug material from Avisa Pharma Solutions, Inc. for potential treatment of COVID-19. The requirement must be fulfilled by the same vendor currently producing non-cGMP material for the same project under Contract No. 75N95021P00063 to ensure consistency. Quotations are due by February 7, 2022. The award is anticipated to be made on February 10, 2022 without full and open competition due to the need for material source consistency.
No set-aside designation is used. The main NAICS code is 325412 and PSC code is Q1PX. The current contractor is Avisa Pharma Solutions, Inc. The requirement is for 2-3 kilograms of cGMP GS-441524 to be delivered within 18 weeks of award. Performance will take place at the contractor's location in Durham, North Carolina. Responses should include pricing, delivery schedule, and evidence of technical capability and experience manufacturing cGMP GS-441524 at scale.
Notice text
THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).
The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Avisa Pharma Solutions, Inc. (dba Cambrex), 3501 Tricenter Blvd Ste C, Durham, NC 27713-1868. To ensure consistency among material, the current requirement must be manufactured by the same vendor that is manufacturing the non-GMP material for the same project under Contract No. 75N95021P00063. Therefore, this acquisition is restricted to Avisa Pharma Solutions, Inc. (dba Cambrex).
The purpose of this acquisition is to obtain 2-3Kg of cGMP GS-441524.
See attachments for complete requirement details.
Files
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | Total Small Business | |
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity